Following Pedro Granadillo’s last HAE Sell transaction on December 04, 2017, the stock climbed by 58.7%.
Based on Haemonetics Corp’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $242 million and quarterly net profit of $18.73 million. In comparison, last year the company earned revenue of $225 million and had a net profit of $20.1 million. HAE’s market cap is $5.94B and the company has a P/E ratio of 287.7. Currently, Haemonetics Corp has an average volume of 605.3K.
Pedro Granadillo’s trades have generated a -25.6% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Haemonetics Corp. is a healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other.